Phase 2 N=34 Docetaxel and Epirubicin in Advanced Gastric Cancer
Stomach Neoplasms
Primary: Overall Survival — 13.4 month
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=54 RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment
Stomach Neoplasm
Primary: Progression-free Survival Rate at 4-month (16 Weeks) — 18.4 percentage of participants
Phase 2 N=18 Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer
Stage T3-4NxM0 Gastric Cancer
Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants
Phase 2 N=21 Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP
Advanced Gastric Cancer
Primary: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) — 3 participants
Phase 2 N=53 Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer
Gastric Cancer
Primary: Percentage of Participants With Objective Response (Objective Response Rate) — 32.1; 67.9 percentage of responders
Phase 3 N=656 Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
Advanced Gastric Cancer
Primary: Overall Survival (OS) — 5.39; 4.34 Months
Phase 2 N=39 FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Gastro-Esophageal Junction Adenocarcinoma · Gastric Cancer
Primary: Objective Response Rate — 15 Participants
Phase 2 N=60 Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
Esophageal Neoplasms · Stomach Neoplasms · Neoplasm Metastasis
Primary: Median Progression-Free Survival (PFS) — 6.97 survival time in months
Phase 2 N=96 Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial
Gastric Cancer
Primary: Response Rate — 28.9; 26.1 percentage of participants
Phase 1 N=20 TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
Gastric Adenocarcinoma · GastroEsophageal Cancer
Primary: Percentage of Participants With Progression-free Survival at 6 Months — 40 percent of participants
Phase 2 N=39 Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
Adenocarcinoma of the Gastroesophageal Junction · Diffuse Adenocarcinoma of the Stomach · Intestinal Adenocarcinoma of the Stomach
Primary: Response Rates (RR) in Metastatic Gastric/GE Junction Tumors — 2; 9; 3; 16 participants
Phase 2 N=44 Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
Adenocarcinoma of the Gastroesophageal Junction · Metastatic Gastric Cancer · Advanced Unresectable Gastric Cancer
Primary: The Proportion of Patients With Objective Response (Complete Response or Partial Response) — 0.409 Proportion of patients — p=0.0012
Phase 3 N=521 Trial of Adjuvant Chemotherapy for Gastric Cancer
Stomach Cancer
Primary: Relapse-free Survival — 50.0; 60.2 percentage of participants
Phase 2 N=69 Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer
Neoplasm, Gastric
Primary: Objective Best Tumor Response — 1; 15; 22; 24 participants
Phase 2 N=40 Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
Gastric Cancer
Primary: Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments — 40 percentage of participants
Phase 2 N=40 Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Gastric Adenocarcinoma · Gastro-esophageal Junction Adenocarcinoma
Primary: Progression-free Survival (PFS) — 5.257 months
Phase 2 N=80 Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: RR — 15 Participants
Phase 2 N=39 FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Gastroesophageal Cancer · Gastric Cancer
Primary: Progression Free Survival — 7.8 months
Phase 2 N=39 Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
Esophageal Cancer · Gastric Cancer
Primary: Time to Progression — 6.6 months
Phase 2 N=30 Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
Gastric Cancer · Stomach Cancer
Primary: Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab — 40 percentage of paticipants
Phase 2 N=52 Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer
Gastric Adenocarcinoma · Barrett Esophagus
Primary: Objective Response Rate (ORR) — 3.92 Participants (%)
Phase 2 N=254 Docetaxel and Oxaliplatin in Gastric Cancer
Stomach Neoplasms
Primary: Time to Progression — 4.50; 7.66; 5.55 Months
Phase 3 N=855 Trial of Adjuvant Chemotherapy for Gastric Cancer
Stomach Cancer
Primary: Relapse-free Survival Rate — 67.0; 64.9 percentage of participants
Phase 2 N=39 Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
Gastric Cancer
Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants
Phase 3 N=584 ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
Gastric Cancer
Primary: Overall Survival (OS) - Percentage of Participants With an Event — 62.8; 56.8 percentage of participants
Phase 2 N=35 Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stomach Cancer · Gastric (Stomach) Cancer · Neoplasm of Cardioesophageal Junction
Primary: Progression-Free Survival (PFS) — 9 Participants
Phase 3 N=1,053 A Safety and Efficacy Study in Patients With Gastric Cancer
Gastric Cancer
Primary: Median Survival — 8.6; 7.9 Months — p=0.1983
Phase 3 N=267 Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
Advanced or Metastatic Gastric Cancer
Primary: Progression Free Survival(PFS) — 2.6; 1.8 month
Phase 3 N=711 Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer
Gastric Cancer
Primary: Overall Survival — 16.0; 15.1 Months — p=0.039
Phase 3 N=530 Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
Gastric Cancer
Primary: Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1 — 60.24; 66.82 percentage…